The first-in-class exportin-1 (XPO1) inhibitor selinexor is FDA approved in recurrent and refractory multiple myeloma, has received accelerated approval in diffuse large B cell lymphoma and is currently under evaluation in more than sixty clinical trials for haematological malignancies and solid tumours. Here, XPO1 is linked to plasma cell myeloma.